Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial.
PURPOSE COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN COPE was a multicenter, randomized (2:1), noncomparative phase II trial. Arm A underwent serial plasma profiling...